China NMPA IVD Registration
Manufacturers looking to market their in vitro diagnostic (IVD) medical devices in China must register with the National Medical Products Administration (NMPA), China’s central authority for medical device regulation, formerly known as the China Food and Drug Administration (CFDA). Whether you’re introducing a new IVD test kit, reagent, or instrument, Cisema helps you achieve regulatory approval through expert guidance on classification, technical documentation, and compliance.
Understanding NMPA IVD Registration
To access the Chinese market, all foreign manufacturers must first appoint an NMPA Legal Agent, who serves as the official liaison with Chinese authorities throughout the product lifecycle. Submitting comprehensive applications that adhere to NMPA standards is crucial for successful registration.
The classification of IVDs is based on the NMPA’s IVD Classification Catalogue, which is updated regularly. Products are classified into Class I, II, or III depending on their risk level.
IVDs not yet included in the catalogue may still be classified via the Rules for IVD Classification or by requesting an official opinion from the NMPA. If unclear, manufacturers can apply for classification determination through the NMPA.
A valid home country approval is currently required for foreign manufacturers, though upcoming regulatory reforms may soon relax this prerequisite.
IVD Registration, Testing, & Clinical Evaluation in China
Registering In Vitro Diagnostics (IVD) in China is governed by the National Medical Products Administration (NMPA) and can take several months up to 2 years or more, depending on the device classification and complexity. Manufacturers must compile a comprehensive application dossier which should include:
Registering In Vitro Diagnostics (IVD) in China is governed by the National Medical Products Administration (NMPA) and can take several months up to 2 years or more, depending on the device classification and complexity.
Manufacturers must compile a comprehensive application dossier which should include:
Once submitted, the NMPA conducts a preliminary administrative check before proceeding to a technical review. During this phase, the agency may raise supplementary information requests to clarify aspects of the data, test reports, or clinical evaluation. For imported IVDs, the NMPA may also perform an on-site inspection of the overseas manufacturing facility to verify quality system compliance.
Upon successful completion of all reviews, the NMPA issues a the Registration Certificate. This certificate is valid for five years and must be renewed prior to expiration to maintain market access.
Adherence to all relevant NMPA requirements, including timely fee payments, proper dossier structure, and accurate technical and clinical data, is critical to achieving successful IVD registration in China.
Our IVD Registration Services
Cisema guides you through the entire NMPA IVD registration dossier process, ensuring compliance, reducing time-to-market, and minimizing risk.
Our services include:
- Predicate devices
- Overseas clinical data
- Class i filings
- Class ii & iii device registrations
- Innovative Device approvals
- Priority Review or Conditional Approvals
- Greater Bay Area fast-track (Hong Kong listing required)
- Emergency use
- Hainan Pilot Zone entry
Once submitted, the NMPA conducts a preliminary administrative check before proceeding to a technical review. During this phase, the agency may raise supplementary information requests to clarify aspects of the data, test reports, or clinical evaluation. For imported IVDs, the NMPA may also perform an on-site inspection of the overseas manufacturing facility to verify quality system compliance.
Upon successful completion of all reviews, the NMPA issues a the Registration Certificate. This certificate is valid for five years and must be renewed prior to expiration to maintain market access.
Adherence to all relevant NMPA requirements, including timely fee payments, proper dossier structure, and accurate technical and clinical data, is critical to achieving successful IVD registration in China.
Request a Proposal from Our Life Sciences Team to Get Approval for Your IVD in China
Let Cisema help turn your plans into reality.
Explore Related Services
Whether you’re just starting out or are a blue-chip, access our wide range of services and outsourcing solutions to help your business thrive.
NMPA Legal Agent
We are your authorized representative in China, and fulfill your NMPA registrations, filings and renewal applications as well as ensuring compliance with quality and PMS requirements.
China Clinical Trials
You may be required to provide supplementary clinical data on Chinese patients or conduct a full trial in China.Our clinical research team will advise you, prepare the study protocol and assist setting up the clinical trial in China.
China IVD Quality Compliance
We help you achieve and ensure ongoing compliance with Chinese requirements.Our experts prepare and assist you for official NMPA inspections.
NMPA IVD Type Testing
Our on-site test engineers coordinate and supervise type tests of your IVDs in NMPA-accredited laboratories.
Drug Device Combination Products
We assist with the classification, authorization, and compliance of combination products in China, whether drug or device led.
IVD PMS & Vigilance
The NMPA is placing greater focus on PMS such as more in-China sampling inspections and regular standard changes.Our specialist PMS team means you stay up to date with the many aspects of compliance.
IVD Regulatory Outsourcing
If you are seeking specific specialist expertise or have ongoing resource-intensive needs, we have a variety of solutions to meet your needs.
